Kilitch Drugs (India) Q1 Results FY27: Date, Revenue Estimates, Key Catalysts and Share Price Target
- July 9, 2026
- Posted by: Kashish Aggarwal
- Category: News
Kilitch Drugs (India) CMP Rs.183. Q1 FY27E revenue Rs.61-70 Cr. PAT estimate Rs.3-4 Cr. 12-month target Rs.220-243.
Kilitch Drugs (India) Q1 Results FY27 is coming into focus as investors position ahead of the July-August 2026 results season, with Kilitch Drugs (India) shares trading at Rs.183 against a market capitalisation of Rs.661 Cr and a price-to-earnings multiple of Not meaningful. As a pharmaceuticals and life sciences name on the NSE and BSE, Kilitch Drugs (India) enters the Kilitch Drugs (India) Q1 Results FY27 print with the Street watching revenue momentum, margin trajectory and management commentary on FY27 guidance.
This Kilitch Drugs (India) Q1 Results FY27 preview is built on a trailing-growth framework applied to the company’s Q1 FY26 base of Rs.46 Cr revenue and Rs.2 Cr net profit, using the most recent year-on-year growth signal from Q4 FY26. This Q1 prediction is a Uniresearch trailing-growth projection, not a formal analyst estimate, and should be read alongside the company’s own guidance once released.
Get Free Investment Predictions and Kilitch Drugs (India) Research at Univest
About Kilitch Drugs (India)
Kilitch Drugs (India) (NSE: KILITCH) operates in the pharmaceuticals and life sciences space and is tracked on Univest under its NSE and BSE listings. Ahead of the Kilitch Drugs (India) Q1 Results FY27 print, the company’s most recent reported quarter (Q4 FY26) shows revenue of Rs.90 Cr and net profit of Rs.15 Cr, forming the base against which the Kilitch Drugs (India) Q1 Results FY27 estimates in this article are built. This Kilitch Drugs (India) Q1 Results FY27 snapshot is intended as a starting point for research, not a substitute for the company’s own disclosures.
Kilitch Drugs (India) Q1 FY27 Estimates
| Metric | Q1 FY27E (Range) | Q1 FY26 Actual | YoY Growth |
|---|---|---|---|
| Revenue (Rs. Cr) | 61-70 | 46 | +43.2% |
| Net Profit / PAT (Rs. Cr) | 3-4 | 2 | +45.6% |
| Results Date | July-August 2026 (indicative) | ||
| 12-Month Target (Uniresearch Estimate) | Rs.220-243 | ||
Univest, a SEBI-Registered Investment Advisor, Tracks Kilitch Drugs (India) Ahead of Q1 FY27 Results
Key Catalysts to Watch
1. CDMO Pipeline Visibility
Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility is one of the primary variables that analysts are tracking ahead of Kilitch Drugs (India)’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Kilitch Drugs (India) share price target or faces renewed pressure.
2. New Product Approvals
New product approvals and launches adding to the domestic and export portfolio is one of the primary variables that analysts are tracking ahead of Kilitch Drugs (India)’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Kilitch Drugs (India) share price target or faces renewed pressure.
3. Capacity Scale-Up
Operating leverage from scale-up in recently commissioned manufacturing capacity is one of the primary variables that analysts are tracking ahead of Kilitch Drugs (India)’s Q1 FY27 results and FY27 guidance. The market’s reaction to management commentary on this factor will likely determine whether the stock can sustain a move toward the Kilitch Drugs (India) share price target or faces renewed pressure.
Download the Univest iOS App or Univest Android App to track Kilitch Drugs (India)’s live price and Q1 FY27 result updates.
Key Risks to the Kilitch Drugs (India) Q1 Results FY27 Outlook
- Pricing pressure in key export markets, particularly the US generics segment.
- Regulatory or plant compliance issues affecting supply continuity.
- R&D and capacity expansion costs weighing on near-term profitability.
Q4 FY26 Performance Context for the Kilitch Drugs (India) Q1 Results FY27 Print
Kilitch Drugs (India) closed Q4 FY26 with revenue of Rs.90 Cr and net profit of Rs.15 Cr, a year-on-year revenue change of +43.2% and PAT change of +45.6% versus Q4 FY25. This base underpins the Kilitch Drugs (India) Q1 Results FY27 projection used in this preview and should be read alongside the company’s own Kilitch Drugs (India) Q1 Results FY27 commentary once reported.
Technical Analysis Ahead of Kilitch Drugs (India) Q1 Results FY27
Kilitch Drugs (India) shares last traded at Rs.183. For the current 52-week high and low, support and resistance levels, investors should check the live chart on the Univest app or the NSE website, since these levels move intraday and are not reproduced here to avoid stale data.
Share Price Target Based on the Kilitch Drugs (India) Q1 Results FY27 Outlook
3-6 Month Target
Over a 3-6 month horizon, the Kilitch Drugs (India) Q1 Results FY27 trailing-growth framework points to a range of Rs.192-206 for Kilitch Drugs (India), contingent on the Kilitch Drugs (India) Q1 Results FY27 print matching or beating the trailing growth trend.
12-Month Target
The 12-month target (Uniresearch estimate) tied to this Kilitch Drugs (India) Q1 Results FY27 view for Kilitch Drugs (India) works out to Rs.220-243, built on the same trailing revenue growth trend and current valuation multiple. Tracking with a constructive bias is how Univest research categorises the stock heading into Kilitch Drugs (India) Q1 Results FY27, not a formal Buy or Sell call.
FY27-28 Outlook
Looking out to FY27-28, a sustained continuation of the growth trajectory implied by this Kilitch Drugs (India) Q1 Results FY27 analysis would put Kilitch Drugs (India) in a Rs.251-284 range, though this is sensitive to sector-wide demand, cost trends and any change in the company’s competitive position.
What to Watch in the Kilitch Drugs (India) Q1 Results FY27 Print
- Revenue and PAT versus the Kilitch Drugs (India) Q1 Results FY27 estimate range in this preview.
- Management commentary on FY27 growth guidance and margin trajectory relevant to the Kilitch Drugs (India) Q1 Results FY27 narrative.
- Steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility
- Pricing pressure in key export markets, particularly the US generics segment
Conclusion on Kilitch Drugs (India) Q1 Results FY27
Kilitch Drugs (India) enters the Q1 FY27 results season trading at Rs.183, with the 12-month Uniresearch target range of Rs.220-243 reflecting a tracking with a constructive bias stance. Investors tracking the Kilitch Drugs (India) Q1 Results FY27 print should watch the catalysts and risks above and consult a SEBI-registered advisor before making investment decisions around the results.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Kilitch Drugs (India) Q1 Results FY27
When are Kilitch Drugs (India) Q1 FY27 results expected?
Ans. Kilitch Drugs (India)’s Q1 FY27 results are expected in the July-August 2026 window, in line with the broader NSE and BSE results season for the quarter ending June 2026.
What is the Kilitch Drugs (India) Q1 FY27 revenue estimate?
Ans. The Uniresearch trailing-growth estimate for Kilitch Drugs (India)’s Q1 FY27 revenue is Rs.61-70 Cr, based on the Q1 FY26 base of Rs.46 Cr.
What is the Kilitch Drugs (India) share price target?
Ans. The 12-month Uniresearch estimate for Kilitch Drugs (India) share price target is Rs.220-243, based on trailing growth and current valuation multiples.
Is Kilitch Drugs (India) a good buy before Q1 FY27 results?
Ans. Kilitch Drugs (India) is tracking with a constructive bias heading into Q1 FY27 results. Investors should weigh the catalysts and risks in this article and consult a SEBI-registered advisor before investing.
What should investors watch in Kilitch Drugs (India)’s Q1 FY27 results?
Ans. Key items include revenue and PAT versus estimates, management commentary on FY27 guidance, and steady traction in the CDMO and contract manufacturing pipeline supporting revenue visibility.
Where can I track Kilitch Drugs (India) share price live?
Ans. Kilitch Drugs (India) share price can be tracked live on the Univest app and website, along with research updates from SEBI-registered analysts.
